Published in Clin Cancer Res on March 13, 2012
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res (2013) 1.15
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol (2015) 0.96
Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Front Immunol (2014) 0.93
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res (2015) 0.88
Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol (2013) 0.86
Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium. Oncoimmunology (2016) 0.84
Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology (2015) 0.77
Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right? Cancer Prev Res (Phila) (2013) 0.76
Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer. Oncoimmunology (2014) 0.75
Spleen cells from young donors eradicate large tumors--letter. Clin Cancer Res (2012) 0.75
The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci Immunol (2016) 0.75
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med (1994) 5.28
The aging immune system: primer and prospectus. Science (1996) 4.86
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
Independent modes of transcriptional activation by the p50 and p65 subunits of NF-kappa B. Genes Dev (1992) 3.47
Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol (2005) 3.20
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 2.34
A unique tumor antigen produced by a single amino acid substitution. Immunity (1995) 2.33
Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood (2010) 2.31
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med (1997) 2.00
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res (2010) 1.91
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol (2008) 1.69
Spontaneous lesions in aging FVB/N mice. Toxicol Pathol (1997) 1.61
Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) 1.60
Gain and loss of T cell subsets in old age--age-related reshaping of the T cell repertoire. J Clin Immunol (2011) 1.48
A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science (2006) 1.44
Single-cell analyses reveal two defects in peptide-specific activation of naive T cells from aged mice. J Immunol (2001) 1.42
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med (2010) 1.40
Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol (2010) 1.40
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer (2011) 1.36
Targeting stroma to treat cancers. Semin Cancer Biol (2011) 1.33
Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells. J Exp Med (2002) 1.24
A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology (2012) 1.20
Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol (2009) 1.18
Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma (2008) 1.16
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun (2005) 1.15
Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med (1985) 1.13
Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol (2004) 1.09
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell (2011) 1.02
Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med (1981) 1.02
Incidence of spontaneous neoplasms in breeding and retired breeder BALB-cCr mice throughout the natural life span. Int J Cancer (1972) 1.01
Immunoregulation by ultraviolet light-III. Enhancement of suppressor cell activity in older animals. Exp Gerontol (1978) 0.92
Tracking the common ancestry of antigenically distinct cancer variants. Clin Cancer Res (2001) 0.90
Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells. Am J Transplant (2011) 0.90
Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8). Glycoconj J (2010) 0.81
Incidence of spontaneous tumors in laboratory rats. Exp Pathol (1985) 0.78
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol (2006) 4.52
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47
Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol (2010) 4.39
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol (2006) 3.73
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol (2008) 3.71
Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol (2013) 3.67
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med (2009) 3.55
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics (2005) 2.91
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A (2007) 2.67
Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol (2004) 2.63
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Bystander elimination of antigen loss variants in established tumors. Nat Med (2004) 2.53
Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol (2008) 2.48
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26
Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol (2008) 2.25
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res (2008) 2.14
HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A (2005) 2.11
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Immune epitope database analysis resource. Nucleic Acids Res (2012) 2.09
Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol (2008) 2.07
Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res (2008) 2.07
STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A (2004) 2.06
Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 2.02
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
The aspect ratio (dome/neck) of ruptured and unruptured aneurysms. J Neurosurg (2003) 2.00
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 1.98
Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. J Immunol (2002) 1.97
Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 1.93
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res (2005) 1.90
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89
Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med (2007) 1.82